Rivaroxaban for the treatment of consumptive coagulopathy associated with a vascular malformation.

Abstract

The localized activation of coagulation in vascular malformations can lead to a consumptive coagulopathy characterized by elevated D-dimers and a consumption of fibrinogen and platelets, eventually giving rise to a bleeding tendency. By reducing coagulation activation, anticoagulant treatment with heparin is able to limit this haemostatic dysregulation and the associated bleeding diathesis. Here, we present a case of a consumptive coagulopathy due to a large venous malformation with a sustained correction of the fibrinogen depletion and associated bleeding tendency both with subcutaneous enoxaparin and with the oral factor Xa inhibitor rivaroxaban.

• Authors: Christophe Vandenbriele, Thomas Vanassche, Marijke Peetermans, Peter Verhamme, Kathelijne Peerlinck
• Journal: Journal of thrombosis and thrombolysis (J Thromb Thrombolysis) Vol. 38 Issue 1 Pg. 121-3 (Jul 2014) ISSN: 1573-742X [Electronic] Netherlands
• PMID: 24202701 (Publication Type: Case Reports, Journal Article)

Chemical References

• Factor Xa Inhibitors
• Fibrin Fibrinogen Degradation Products
• Morpholines
• Thiophenes
• fibrin fragment D
• Rivaroxaban

Topics

• Administration, Oral
• Adult
• Disseminated Intravascular Coagulation (blood, complications, drug therapy)
• Factor Xa Inhibitors (administration & dosage)
• Fibrin Fibrinogen Degradation Products (metabolism)
• Humans
• Male
• Morpholines (administration & dosage)
• Rivaroxaban
• Thiophenes (administration & dosage)
• Vascular Malformations (blood, complications, drug therapy)